NCT06828354View on ClinicalTrials.gov

A Study of SHR-A1811 in Subjects With Ovarian Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811.

DRUG

Paclitaxel Injection

Paclitaxel Injection.

DRUG

Doxorubicin Hydrochloride Liposome Injection

Doxorubicin Hydrochloride Liposome Injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for Injection.

DRUG

Topotecan Hydrochloride for Injection

Topotecan Hydrochloride for Injection.

Trial Locations (2)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

430030

RECRUITING

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY